Trial Profile
A multicenter, double-blind, randomized, parallel-group study to compare the effect of 12 weeks treatment with vildagliptin (50mg qd [once daily], 50mg bid [twice daily], 100mg qd) to placebo in patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 08 Oct 2006 New trial record.